MRNA Stock Summary and Trading Ideas (Moderna | NASDAQ:MRNA)

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna trades on the NASDAQ stock market under the symbol MRNA.

As of November 14, 2024, MRNA stock price declined to $41.37 with 465,547 million shares trading.

MRNA has a beta of 0.41, meaning it tends to be less sensitive to market movements. MRNA has a correlation of 0.01 to the broad based SPY ETF.

MRNA has a market cap of $15.90 billion. This is considered a Large Cap stock.

Last quarter Moderna reported $2 billion in Revenue and $.03 earnings per share. This beat revenue expectation by $612 million and exceeded earnings estimates by $1.93.

In the last 3 years, MRNA traded as high as $376.65 and as low as $41.08.

The top ETF exchange traded funds that MRNA belongs to (by Net Assets): VTI, VOO, VO, QQQ, VUG.

MRNA has underperformed the market in the last year with a price return of -41.1% while the SPY ETF gained +37.2%. MRNA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -50.1% and -24.4%, respectively, while the SPY returned +10.5% and +2.9%, respectively.

MRNA support price is $40.91 and resistance is $43.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA shares will trade within this expected range on the day.